Treatment with benzodiazepines, non-benzodiazepine anxiolytics/ hypnotics/sedatives, neuroleptics, opioids, barbiturates, diclofenac, valproate, phenytoin, ethosuximide within 2 weeks prior to enrollment (discontinuation for the purpose of study enrollment is permitted only if considered safe by the Investigator and approved by the Medical Monitor).Other documented clinically significant condition (including an unstable medical condition, chronic disease other than narcolepsy with cataplexy, or history or presence of another neurological disorder) that might affect the subject's safety and/or interfere with the conduct of the study in the opinion of the Investigator.Parent(s) or guardian(s) unable to comply with the requirements of the study for any reason, in the opinion of the Investigator.Inability to understand assent or follow study instructions for any reason, in the opinion of the Investigator.Be willing to spend 2 additional nights in the clinic for PK evaluation In addition to the above inclusion criteria, subjects participating in the PK evaluation must meet the following inclusion criteria:ħ. If currently treated with Xyrem, must have been taking unchanged doses (twice nightly dosing no higher than 9 g/night) of Xyrem, and stimulants, if applicable, for the treatment of narcolepsy symptoms for at least 2 months prior to screening.Be willing to spend the required number of nights (2 to 3) in a sleep laboratory for PSG evaluations. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |